Q4 2024 Holdings
Filed 2025-02-14 | 72 holdings | $6.6B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals Inc(MDGL) | COM | 558868105 | $615.2M | 1,993,687 | 9.3% |
| Argenx SE(ARGX) | SPONSORED ADR | 04016X101 | $414.2M | 673,497 | 6.3% |
| Natera Inc(NTRA) | COM | 632307104 | $410.5M | 2,593,323 | 6.2% |
| Axsome Therapeutics Inc(AXSM) | COM | 05464T104 | $342.8M | 4,051,365 | 5.2% |
| PTC Therapeutics Inc(PTCT) | COM | 69366J200 | $333.7M | 7,393,127 | 5.0% |
| Avidity Biosciences Inc(RNA) | COM | 05370A108 | $230.7M | 7,932,870 | 3.5% |
| Rocket Pharmaceuticals Inc(RCKT) | COM | 77313F106 | $222.3M | 17,687,772 | 3.4% |
| Alkermes PLC(ALKS) | SHS | G01767105 | $217.4M | 7,557,835 | 3.3% |
| Stryker Corporation(SYK) | COM | 863667101 | $212.5M | 590,221 | 3.2% |
| Protagonist Therapeutics Inc(PTGX) | COM | 74366E102 | $212.2M | 5,498,545 | 3.2% |
| Insmed Inc(INSM) | COM PAR $.01 | 457669307 | $208.1M | 3,014,558 | 3.1% |
| Penumbra Inc(PEN) | COM | 70975L107 | $204.8M | 862,450 | 3.1% |
| Akero Therapeutics Inc(AKRO) | COM | 00973Y108 | $190.8M | 6,859,823 | 2.9% |
| Tarsus Pharmaceuticals Inc(TARS) | COM | 87650L103 | $179.2M | 3,236,549 | 2.7% |
| Merus N V | COM | N5749R100 | $175.3M | 4,169,393 | 2.7% |
| Acadia Pharmaceuticals Inc(ACAD) | COM | 004225108 | $159.7M | 8,705,501 | 2.4% |
| Bruker Corp(BRKR) | COM | 116794108 | $145.4M | 2,481,119 | 2.2% |
| Immunocore Hldgs PLC(IMCR) | ADS | 45258D105 | $143.7M | 4,869,798 | 2.2% |
| Radnet Inc(RDNT) | COM | 750491102 | $138.2M | 1,978,582 | 2.1% |
| Cytokinetics Inc(CYTK) | COM NEW | 23282W605 | $128.0M | 2,721,158 | 1.9% |
| Dyne Therapeutics Inc(DYN) | COM | 26818M108 | $123.0M | 5,218,641 | 1.9% |
| Apogee Therapeutics Inc(APGE) | COM | 03770N101 | $122.9M | 2,712,097 | 1.9% |
| Establishment Labs Hldgs Inc(ESTA) | COM | G31249108 | $118.4M | 2,569,687 | 1.8% |
| Masimo Corp(MASI) | COM | 574795100 | $112.9M | 683,294 | 1.7% |
| Verona Pharma PLC(VRNA) | SPONSORED ADS | 925050106 | $84.6M | 1,821,019 | 1.3% |
| Spyre Therapeutics Inc(SYRE) | COM NEW | 00773J202 | $84.3M | 3,621,996 | 1.3% |
| Ultragenyx Pharmaceutical in(RARE) | COM | 90400D108 | $82.8M | 1,968,002 | 1.3% |
| Globus MED Inc(GMED) | CL A | 379577208 | $80.4M | 972,000 | 1.2% |
| ZAI LAB LTD(ZLAB) | ADR | 98887Q104 | $65.7M | 2,509,119 | 1.0% |
| Arvinas Inc(ARVN) | COM | 04335A105 | $63.9M | 3,334,308 | 1.0% |
| Cargo Therapeutics Inc(CRGX) | COM | 14179K101 | $59.5M | 4,124,859 | 0.9% |
| 89Bio Inc(ETNBGBP) | COM | 282559103 | $58.5M | 7,478,061 | 0.9% |
| Stoke Therapeutics Inc(STOK) | COM | 86150R107 | $56.5M | 5,123,525 | 0.9% |
| Xencor Inc(XNCR) | COM | 98401F105 | $55.2M | 2,402,883 | 0.8% |
| CG Oncology Inc(CGON) | COM | 156944100 | $48.8M | 1,701,216 | 0.7% |
| Immatics N.v(IMTX) | SHS | N44445109 | $46.5M | 6,540,540 | 0.7% |
| Urogen Pharma LTD(URGN) | COM | M96088105 | $40.8M | 3,834,794 | 0.6% |
| Oruka Therapeutics Inc(ORKA) | COM | 687604108 | $37.7M | 1,945,649 | 0.6% |
| Orchestra Biomed Hldgs Inc(OBIO) | COM | 68572M106 | $32.8M | 8,206,162 | 0.5% |
| Neurogene Inc(NGNE) | COM | 64135M105 | $30.9M | 1,350,256 | 0.5% |
| Replimune Group Inc(REPL) | COM | 76029N106 | $25.0M | 2,065,010 | 0.4% |
| Lenz Therapeutics Inc(LENZ) | COM | 52635N103 | $24.9M | 863,389 | 0.4% |
| GH Research PLC(GHRS) | ORDINARY SHARES | G3855L106 | $23.3M | 3,327,129 | 0.4% |
| Cullinan Therapeutics Inc(CGEM) | COM | 230031106 | $20.8M | 1,705,960 | 0.3% |
| Rapt Therapeutics Inc(RAPTEUR) | COM | 75382E109 | $18.6M | 11,764,000 | 0.3% |
| Roivant Sciences LTD(ROIV) | SHS | G76279101 | $17.2M | 1,454,273 | 0.3% |
| Sage Therapeutics Inc(SG7) | COM | 78667J108 | $16.3M | 3,002,370 | 0.2% |
| Uniqure NV(QURE) | SHS | N90064101 | $16.0M | 903,625 | 0.2% |
| Taysha Gene Therapies Inc(TSHA) | COM SHS | 877619106 | $15.0M | 8,672,630 | 0.2% |
| Tourmaline BIO Inc(TRML) | COM | 89157D105 | $14.9M | 736,681 | 0.2% |